Similar articles for PMID: 15795284

Year	Number of Results
1943	1
1999	1
2000	1
2001	1
2002	8
2003	7
2004	22
2005	23
2006	18
2007	18
2008	20
2009	22
2010	16
2011	16
2012	15
2013	4
2014	5
2015	4
2016	9
2017	8
2018	7
2019	16
2020	3
2021	4
2022	9
2023	1
2024	0

1

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.

Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Reeves JD, et al. J Virol. 2005 Apr;79(8):4991-9. doi: 10.1128/JVI.79.8.4991-4999.2005. J Virol. 2005. PMID: 15795284 Free PMC article.

2

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Ray N, et al. J Virol. 2007 Apr;81(7):3240-50. doi: 10.1128/JVI.02413-06. Epub 2007 Jan 24. J Virol. 2007. PMID: 17251281 Free PMC article.

3

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.

Zhuang M, Vassell R, Yuan C, Keller PW, Ling H, Wang W, Weiss CD. Zhuang M, et al. J Virol. 2019 May 15;93(11):e00142-19. doi: 10.1128/JVI.00142-19. Print 2019 Jun 1. J Virol. 2019. PMID: 30894471 Free PMC article.

4

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F. Labrosse B, et al. J Virol. 2006 Sep;80(17):8807-19. doi: 10.1128/JVI.02706-05. J Virol. 2006. PMID: 16912327 Free PMC article.

5

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW. Reeves JD, et al. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20. Proc Natl Acad Sci U S A. 2002. PMID: 12444251 Free PMC article.

6

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V. Poveda E, et al. J Med Virol. 2004 Sep;74(1):21-8. doi: 10.1002/jmv.20141. J Med Virol. 2004. PMID: 15258964 Clinical Trial.

7

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Lu J, et al. J Virol. 2004 May;78(9):4628-37. doi: 10.1128/jvi.78.9.4628-4637.2004. J Virol. 2004. PMID: 15078945 Free PMC article.

8

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. Mink M, et al. J Virol. 2005 Oct;79(19):12447-54. doi: 10.1128/JVI.79.19.12447-12454.2005. J Virol. 2005. PMID: 16160172 Free PMC article.

9

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.

Goubard A, Clavel F, Mammano F, Labrosse B. Goubard A, et al. Antivir Ther. 2009;14(4):597-602. Antivir Ther. 2009. PMID: 19578246

10

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. Xu L, et al. Antimicrob Agents Chemother. 2005 Mar;49(3):1113-9. doi: 10.1128/AAC.49.3.1113-1119.2005. Antimicrob Agents Chemother. 2005. PMID: 15728911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

246 results

Results by year